News & Insights

The U.S. Drug Enforcement Administration (DEA) has issued a new Public Safety Advisory warning communities, healthcare professionals, first

New research suggests that Wegovy, the popular semaglutide-based weight-loss medication, may also help reduce alcohol consumption among

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to

A major change in federal cannabis policy could reshape conversations across healthcare, pharmacy, addiction medicine, and public policy

Fetal fentanyl syndrome (FFS) is an emerging concern in addiction medicine and perinatal health, reflecting the growing impact of fentanyl

A recent randomized clinical trial from Johns Hopkins University highlights the emerging potential of psilocybin-assisted therapy as a novel

Dozens of advocates testified on February 18 at the Connecticut state Capitol in support of new legislation that would authorize the

In recent months, communities in Upstate New York have seen a worrisome rise in nonfatal overdoses linked to synthetic cannabis — commonly

In January 2026, behavioral health and substance use disorder (SUD) professionals nationwide were rocked by an abrupt federal funding

In this comprehensive clinical review published by JAMA, experts examine the current evidence for therapeutic cannabis and cannabinoid use

Alcohol and other substance use disorders (ASUDs) remain chronic, multifaceted, and undertreated medical conditions with profound individual

ARMR Sciences is preparing to launch the first major human clinical trial of a fentanyl vaccine, marking a potentially transformative